Eli Lilly and Co. said it expects to pay $1.42 billion to settle litigation with the U.S. Attorney's Office in Philadelphia involving claims that the company downplayed the adverse effects of Zyprexa when it promoted the psychiatric drug for off-label use. Lilly said it is in advanced talks with prosecutors and is willing to "intensify efforts to resolve these issues."

Related Summaries